New Study: ALK Rearrangement Among Lung Cancer Patients

Nov 11, 2021

Researchers conducted a retrospective study of 20,000 lung cancer patients to analyze ALK gene rearrangement prevalence, offering insights into potential drug therapies. The study highlighted higher rates of ALK rearrangement in non-smokers and Asians, emphasizing the impact of patient demographics on the presence of the gene rearrangement.

Ask episode

Chapters

Transcript

Episode notes

Exploring ALK Rearrangement in Lung Cancer Patients

00:00 • 3min

Analysis of ALK Rearrangement Among Lung Cancer Patients

02:42 • 3min

The identification of an actionable gene mutation or translocation in patients with cancer can give researchers a target for new drug therapies. One such mutation, found in some patients with non-small cell lung cancer (NSCLC), is anaplastic lymphoma kinase (ALK) gene rearrangement. However, the exact population of patients that present with ALK rearrangement has not been fully characterized. Identifying the subpopulation of patients who present with ALK rearrangement may lead to better overall treatment outcomes. Researchers—from University of Mississippi Medical Center, Roche Information Solutions, Roche Diagnostics Corporation, Genesis Research, and Houston Methodist Hospital—conducted a retrospective study of nearly 20,000 patients with advanced NSCLC (aNSCLC). The researchers assessed ALK rearrangement prevalence in the cohort overall and then categorized the data using patient characteristics. Their paper was published on the cover of Oncotarget’s Volume 12, Issue 23, and entitled, “Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States – retrospective real world data”. “We performed a retrospective study of a database to acquire real-world clinical data on the frequency of the translocation in a large pool of patients drawn primarily from community hospitals and practices.” Full blog - https://www.oncotarget.org/2021/11/10/new-study-alk-rearrangement-among-lung-cancer-patients/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28114 DOI - https://doi.org/10.18632/oncotarget.28114 Full text - https://www.oncotarget.com/article/28114/text/ Correspondence to - Eric H. Bernicker - bernicker@houstonmethodist.org Keywords - ALK rearrangement, NSCLC, prevalence About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957